

Index

A

- Acute idiopathic pericarditis, 76
 - Acute tuberculous pericarditis, 76
 - AIDS-defining cancers (ADCs), 17
 - Angiotensin-converting enzyme (ACE), 32
 - Aortic graft infection, 66
 - Aspergillosis, 20
 - Autoimmune disorders (AID),
 - PET/CT, 80–82, 85
 - advantages of, 80
 - autoimmune limbic encephalitis, 85
 - autoimmune pancreatitis, 85
 - autoimmune vasculitis, 80, 81
 - IBD, 81, 82
 - MS, 85
 - polyarteritis nodosa, 81
 - psoriasis, 82
 - RA, 82
 - Sjögren's disease, 85
 - SLE, 81
 - thyroiditis, 85
 - Wegener's Granulomatosis, 81
- Autoimmune limbic encephalitis (ALE), 85
 - Autoimmune vasculitis, 80, 81

B

- Bilateral hip prostheses, 47
- Bilateral renal artery stenosis, 91
- Bilateral total knee replacement, 48
- Broncho-alveolar lavage (BAL)
 - fluid analysis, 34

C

- Candidiasis, 20
- Cardiac implantable electronic devices (CIED), 73, 74
- Cardiac involvement, 34

Cardiac PET/CT

- CIED, 73, 74
 - myocarditis, 76
 - native valve infective endocarditis, 72
 - pericarditis, 75, 76
 - preparation for, 72
 - PVE, 72
- Cardiac sarcoidosis, 34, 35
- Charcot arthropathy, 57, 59
- Charcot neuroarthropathy, 59, 60
- Chronic sarcoidosis, 36, 37
- Colour-Doppler ultrasound, 11
- Contrast enhanced MRI (CMR), 36
- Corticosteroid therapy, 31
- C-reactive protein (CRP)
 - and ESR, 11
- Crohn's disease (CD), 81

D

- Diabetes mellitus (DM), 21, 56
- Diabetic foot infection, 56, 57
- Diabetic foot syndrome
 - Charcot arthropathy, 59
 - Charcot neuroarthropathy, 59
 - early diagnosis, 57
 - estimated risk of, 57
 - primary pathogenetic factors, 58
 - reported studies, 58, 59
- DNA microarray, 44

E

- Etoricoxib, 84
- European Society of Cardiology (ESC)
 - guidelines, 72, 77
- Extra-pulmonary sarcoidosis
 - cardiac involvement, 34, 35
 - lymphadenopathy, 34

F

- FDG Diabetic foot syndrome, Charcot osteoarthropathy, 59
- FDG PET/CT, 3–5, 56–59, 66–69
 - advantages of, 56
 - diabetic foot syndrome
 - Charcot arthropathy, 59
 - Charcot neuroarthropathy, 59
 - Charcot osteoarthropathy, 59
 - early diagnosis, 57
 - estimated risk of, 57
 - primary pathogenetic factors, 58
 - reported studies, 58, 59
- osteomyelitis
 - axial and appendicular skeleton, 56, 57
 - causes, 55
 - definition, 55
 - response assessment, 61
- PUO
 - current guidance and investigational algorithms, 4, 5
 - evidence for, 3
 - limitations of, 4
 - rationale for, 3
 - vascular graft infection
 - diagnostic accuracy, 66
 - drawbacks, 67, 68
 - intense uptake, 67
 - SUVmax, 67, 69
- Febrile neutropenia (FN), 21
- Fever of unknown origin (FUO), 19
- Fungal infections, 20, 21

G

- Giant-cell arteritis, 9, 93
- Graft maximum standardised uptake value (SUVmax), 67

H

- Hematologic malignancies, 20
- Hematopoietic stem cell transplantation, 20
- HIV-associated Kaposi sarcoma, 17
- HIV-associated malignancies, 17–19
- HIV infection
 - and TB coinfection, 19
 - with undifferentiated sarcoma, 16
- HIV lymphadenopathy, 18
- Hodgkin's lymphoma, 18
- HRCT, 31
- Hydroxychloroquine, 84
- Hypermetabolism, 85
- Hypometabolism, 85

I

- Immunodeficiency disorders, 17
 - clinical and radiological features, 16
- F18 Fluorothymidine, 22
 - management, 22
 - medical interventions, 16
 - primary, 15
 - secondary, 15
- Immunosuppressive therapy, 8
- Immunosuppressive therapy on Diagnostic Performance, 11
- Infected knee prosthesis, 49
- Infectious spondylodiscitis, 57
- Infective endocarditis, 72, 75, 96
- Inflammatory bowel disease (IBD), 21, 81, 82
- Inflammatory pseudotumor (IPT), 86
- Invasive fungal infections (IFIs), 20

L

- Large vessel vasculitis, 7
- Lipodystrophy, 19
- Lofgren's syndrome, 30
- Lymphadenopathy, 34, 99
- Lymphoma, 99

M

- Magnetic resonance imaging (MRI), 11, 56–58, 100
- Malignant peritoneal disease, 98
- Medium vessel vasculitis, 10, 12, 93
- Multiple sclerosis (MS), 84
- Myelopathic symptoms, 33
- Myocarditis, 76

N

- Native valve infectious endocarditis, 72
- Neuro-osteoarthropathy, 57
- Neuropathic osteoarthropathy, 60
- Non-AIDS-defining cancers (NADCs), 17
- Non-infected vascular grafts, 94
- Nuclear medicine techniques, 80

O

- Opportunistic infections, 16
- Osteomyelitis (OM), 59
 - acute/chronic type, 55
 - axial and appendicular skeleton, 56, 57
 - causes, 55
 - definition, 55
 - early diagnosis, 55
 - response assessment, 61

P

- Pericarditis, 75, 76, 97
- Periprosthetic joint infection, MSIS, 44
- Peritoneal tuberculosis, 98
- PET/CT, 8–12, 80–82, 85
 - AID
 - abnormally increased
 - glucose metabolism, 80
 - advantage of, 80
 - autoimmune limbic encephalitis, 85
 - autoimmune pancreatitis, 85
 - autoimmune vasculitis, 80, 81
 - IBD, 81, 82
 - MS, 85
 - polyarteritis Nodosa, 81
 - RA, 82
 - Sjögren's disease, 85
 - SLE, 81
 - thyroiditis, 85
 - Wegener's granulomatosis, 81
 - psoriasis, 82
 - vasculitis
 - differential diagnosis, 9
 - FDG, patient management, 11
 - giant-cell arteritis, 9
 - immunosuppressive therapy, 11
 - medium and small
 - vessel vasculitis, 10, 12
 - morphological imaging, 11, 12
 - PET positivity, criteria for, 9
 - Takayasu arteritis, 8
- Plain film radiography (PFR), 58
- Point spread function (PSF) reconstructions, 9
- Polyarteritis nodosa, 81
- Polymyalgia rheumatica, 9
- Pretransplant studies, 20
- Prosthetic joint infection (PJI), 47, 48, 50
 - bilateral hip prostheses, 47
 - bilateral total knee replacement, 48
 - criteria for, 45–46
 - drawbacks of, 49, 51
 - FDG-labelled leukocyte imaging, 51
 - florid inflammatory changes, 44
 - infected knee prosthesis, 49
 - performance of, 50
 - periprosthetic joint infection by MSIS, 44
 - synovial fluid biomarkers, 44
 - synovial fluid leukocyte count, 44
- Prosthetic valve IE (PVE), 72, 73
- Psoas abscess, 94
- Psoriasis, 82
- Psoriatic arthritis (PsA), 82
- Pulmonary sarcoidosis, 31, 34

- PVE, *see* Prosthetic valve IE (PVE)
- Pyrexia of Unknown Origin (PUO), 3–5
 - causes of, 2
- FDG PET/CT
 - Current Guidance and Investigational Algorithms, 4, 5
 - evidence for, 3
 - limitations of, 4
 - Rationale for, 3

R

- Radiolabelled white blood cell scintigraphy
 - with $^{111}\text{In}/^{99\text{m}}\text{Tc}$ -HMPAO, 66
- Rheumatoid arthritis (RA), 82

S

- Sarcoidosis, 30–37, 99
 - characterization, 29
 - ^{18}F -FDG PET/CT, 32
 - cardiac evaluation, 35
 - chronic, 37
 - diagnosis, 33
 - disease prognostication, 37
 - extra-pulmonary, 34, 35
 - ^{18}F -FLT, 33
 - ^{68}Ga -DOTATATE PET/CT, 32–33
 - ^{68}Ga -DOTATOC PET/CT, 33
 - HRCT, 31
 - limitations, 37
 - ^{11}C -Methionine PET, 33
 - muscular involvement, 36
 - patient preparation for, 35, 36
 - prediction and detection of relapse, 37
 - pulmonary sarcoidosis, 34
 - treatment response monitoring, 36, 37
 - type II sarcoidosis, 30
 - Skeletal tuberculosis, 99
 - Small vessel vasculitis, 10, 12
 - Solid organ transplantation, 20
 - Somatostatin receptor (SSTR), 33, 36
 - Somatostatin receptor imaging (SSRI), 33
 - Spondylodiscitis, 100
 - SUVmax ratio, 9, 57, 69
 - Systemic lupus erythematosus (SLE), 81
- T**
- Takayasu arteritis, 8, 91, 92
 - Thyroiditis, 85
 - Tuberculosis, 99
 - Type II sarcoidosis, 30

U

Ulcerative colitis (UC), 81

V

Vascular graft infection, 66–69, 95

advantages of CT, 66

complications, 65

early-onset infection, 65

FDG PET/CT

diagnostic accuracy, 66

drawbacks to, 67, 68

intense uptake, 67

SUVmax cut-off, 67, 69

late-onset infection, 65

radiolabelled white blood cell scintigraphy,

¹¹¹In/^{99m}Tc-HMPAO, 66

Vascular graft insertion, 65

Vasculitides, 7

Vasculitis

differential diagnosis, 9

FDG, patient management, 11

FDG PET, monitoring response

to therapy, 11

giant-cell arteritis, 9

immunosuppressive therapy, 11

medium and small vessel vasculitis, 10, 12

morphological imaging, 11, 12

PET positivity, criteria for, 9

Takayasu arteritis, 8

Vessel vasculitis, 92

W

Wegener's granulomatosis, 81

White blood cell/BM imaging, 45